Inspections, Compliance, Enforcement, and Criminal Investigations
Catawba Radiological Associates, Inc. 05-Dec-01
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Atlanta District Office
60 Eighth Street, N.E.
Atlanta, Georgia 30309
December 5, 2001
VIA FEDERAL EXPRESS
Inspection ID: 1057340008
Catawba Radiological Associates, Inc.
235 18th Street SE
Hickory, NC 28602
Dear Ms. Goodnight:
Your facility was inspected on 11/12/01 by a representative of the North Carolina Department of Environment & Natural Resources (DENR), Division of Radiation Protection, acting on behalf of the Food and Drug Administration (FDA) . This inspection revealed that your facility failed to comply with certain Quality Standards for
Mammography as specified in Title 21, Code of Federal Regulations
(CFR), Part 900.12, as follows:
Mammograms were processed in processor #1, [redacted] located in the mammography room, when it was out of-limits on at least 5 days.
The specific deficiency noted above appeared under the Level 1 heading on your MQSA Facility Inspection Report, which was issued at the close of the inspection. This deficiency may be symptomatic of serious underlying problems that could compromise
the quality of mammography at your facility.
It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA?s regulations. You are responsible for investigating and determining the causes of the deficiencies that the inspection
identifies and promptly initiating permanent corrective actions. If you fail to promptly correct these deficiencies FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:
- impose civil money penalties on a facility of up to $10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.
- suspend or revoke a facility?s FDA certificate for failure to comply with the Standards.
- seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.
Please note that FDA regulations do not preclude a State from enforcing its own State mammography laws and regulations. In some cases, these requirements may be more stringent than FDA?s. When you plan your corrective action(s), therefore, you should consider the more stringent State requirements, if any.
Within 15 working days after receiving this letter, you should notify FDA in writing of:
- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record-keeping procedures, if the non-compliances that were found relate to quality control or other records. (Note: Patient names or identification should be deleted from any copies submitted.)
If your facility is unable to complete the corrective action within 15 working days, you should state the reason for the delay and the time within which corrections will be completed. Please send the original copy of your response to:
Serene A. Kimel, Compliance Officer
U.S. Food and Drug Administration
60 8th St., NE
Atlanta, GA 30309
With a copy to:
North Carolina DENR
Division of Radiation Protection
3825 Barrett Drive
Raleigh, NC 27609-7221
U.S. Food and Drug Administration
5701 Executive Center Drive, Suite 104
Charlotte, NC 28212
Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general
information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet athttp://www.fda.gov/cdrh/mammography/index.html
You may choose to address both FDA and state requirements in your response. If you have any questions regarding this letter or how to ensure you are meeting MQSA Standards please call Thomas Clarida at 704-344-6116.
Ballard H. Graham, Director